5032Mirati is seeking collaboration opportunities for novel oncology assets targeting kinase inhibitors and epigenetic targets. Mirati is also seeking collaborations with investigators and clinical sites interested in exploring program combinations and novel approaches to targeted cancer therapy.

Currently, worldwide rights to all pipeline programs are owned by Mirati Therapeutics except certain Asian rights for Mocetinostat (MGCD103), where the program is partnered with Taiho.


Please contact bd@mirati.com

Mirati’s current collaborations include:



Mirati is collaborating with Foundation Medicine, Inc., on the development of a companion diagnostic (CDx) test for glesatinib.  As part of the collaboration, FoundationOne®, Foundation Medicine’s comprehensive genomic profiling assay for solid tumors, is also being used in the Phase 2 trial to identify those patients most likely to benefit from glesatinib based on their genomic profiles.  Mirati and Foundation Medicine are also collaborating to identify and reach out to physicians with patients screened by Foundation Medicine that might be eligible for Mirati’s trials.



Mirati is collaborating with Guardant Health to develop a circulating tumor DNA (ctDNA) assay for glesatinib. As part of the collaboration, Guardant360, a highly sensitive blood test that looks for tumor mutations within 70 cancer genes, will be used in the Phase 2 trial for glesatinib in patients with NSCLC. Mirati and Guardant Health will also identify and contact physicians with patients screened by Guardant Health who might be eligible for Mirati’s trials.



Mirati has an ongoing clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. Under the agreement, Mirati is running a Phase 1/2 study to evaluate the safety and efficacy of Mirati’s HDAC inhibitor, mocetinostat, in combination with MedImmune’s anti-PD-L1 immune checkpoint inhibitor, durvalumab in NSCLC. Under the collaboration, Mirati will conduct and fund the trial, and MedImmune will supply durvalumab.



Mirati is collaborating with Qiagen to co-develop and commercialize a potential RNA biomarker based companion diagnostic for glesatinib to detect MET exon14 deletion mutations.



Mirati is partnered with Taiho Pharmaceutical for the development and commercialization of mocetinostat in certain Asian territories.